GlycoMimetics Enters Material Definitive Agreement

Ticker: CBIO · Form: 8-K · Filed: Apr 29, 2025 · CIK: 1253689

Glycomimetics INC 8-K Filing Summary
FieldDetail
CompanyGlycomimetics INC (CBIO)
Form Type8-K
Filed DateApr 29, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, 8-k

TL;DR

GlycoMimetics just signed a big deal, details TBD.

AI Summary

On April 28, 2025, GlycoMimetics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Rockville, Maryland, filed an 8-K report detailing this event. The filing does not provide specific details about the agreement or any associated financial figures.

Why It Matters

This filing indicates a significant new contract or partnership for GlycoMimetics, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the agreement.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by GlycoMimetics, Inc.?

The filing does not specify the nature of the material definitive agreement.

Are there any financial terms or dollar amounts associated with this agreement disclosed in the filing?

No, the filing does not disclose any specific financial terms or dollar amounts related to the agreement.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on April 28, 2025.

What is the principal executive office address for GlycoMimetics, Inc.?

The principal executive office address for GlycoMimetics, Inc. is P.O. Box 65, Monrovia, Maryland, 21770.

What is the SIC code for GlycoMimetics, Inc.?

The Standard Industrial Classification (SIC) code for GlycoMimetics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 29, 2025 regarding GLYCOMIMETICS INC (CBIO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing